Maximal entropy inference of oncogenicity from phosphorylation signaling
Abstract
Point mutations in the phosphorylation domain of the Bcr-Abl fusion oncogene give rise to drug resistance in chronic myelogenous leukemia patients. These mutations alter kinase-mediated signaling function and phenotypic outcome. An information theoretic analysis of the correlation of phosphoproteomic profiling and transformation potency of the oncogene in different mutants is presented. The theory seeks to predict the leukemic transformation potency from the observed signaling by constructing a distribution of maximal entropy of site-specific phosphorylation events. The theory is developed with special reference to systems biology where high throughput measurements are typical. We seek sets of phosphorylation events most contributory to predicting the phenotype by determining the constraints on the signaling system. The relevance of a constraint is measured by how much it reduces the value of the entropy from its global maximum, where all events are equally likely. Application to experimental phospho-proteomics data for kinase inhibitor-resistant mutants shows that there is one dominant constraint and that other constraints are not relevant to a similar extent. This single constraint accounts for much of the correlation of phosphorylation events with the oncogenic potency and thereby usefully predicts the trends in the phenotypic output. An additional constraint possibly accounts for biological fine structure.
Additional Information
© 2010 by the National Academy of Sciences. Contributed by Michael E. Phelps, January 29, 2010 (sent for review December 7, 2009). Published online before print March 11, 2010. We are grateful to Professors Amos Golan and Nathan Price who acted as the internal referees of this paper. Professor Michael Fisher kindly commented on the draft manuscript. Funding for the experimental research was provided by National Institutes of Health National Human Genome Research Institute Grant HG002807 (to T.G.G.) and National Cancer Institute Grant 5U54 CA119347 (to T.G.G., J.R.H., and M.E.P.; J.R.H., principal investigator). Author contributions: T.G.G., F.R., and R.D.L. designed research; T.G.G., J.R.H., B.J.S., M.E.P., F.R., and R.D.L. analyzed data; F.R. and R.D.L. performed research; and T.G.G., J.R.H., M.E.P., F.R., and R.D.L. wrote the paper.Attached Files
Published - Graeber2010p9866P_Natl_Acad_Sci_Usa.pdf
Supplemental Material - stxt01.pdf
Files
Name | Size | Download all |
---|---|---|
md5:c3e9bcdfbd92928a2ca22d8225138b64
|
565.9 kB | Preview Download |
md5:7d276c23080d72b969157de4c7f1024e
|
697.8 kB | Preview Download |
Additional details
- PMCID
- PMC2851899
- Eprint ID
- 18388
- Resolver ID
- CaltechAUTHORS:20100521-111915396
- NIH
- HG002807
- National Cancer Institute
- 5U54 CA119347
- Created
-
2010-06-07Created from EPrint's datestamp field
- Updated
-
2021-11-08Created from EPrint's last_modified field